TY - JOUR
T1 - Different effects of simvastatin and losartan on cytokine levels in coronary artery disease
AU - Sadamatsu, Kenji
AU - Shimokawa, Hiroaki
AU - Tashiro, Hideki
AU - Seto, Taku
AU - Kakizoe, Hiroshi
AU - Yamamoto, Kunihiko
N1 - Funding Information:
This work was supported, in part, by grants-in-aid (no. 15256003 and 16209027) from the Japanese Ministry of Education, Sports, Science, and Technology (Tokyo, Japan) and the Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Pharmaceutical Safety (Tokyo, Japan).
PY - 2006
Y1 - 2006
N2 - Background and objective: Use of HMG-CoA reductase inhibitors (statins) and angiotensin II type 1 (AT1) receptor antagonists reduces the incidence of cardiovascular events. The cytokines macrophage colony-stimulating factor (M-CSF) and transforming growth factor (TGF)-β may exert proatherogenic and antiatherogenic effects, respectively. In this study, we examined whether treatment with a statin or an AT1 receptor antagonist alters M-CSF and TGF-β levels in patients with coronary artery disease. Methods: Twenty-seven consecutive patients with coronary artery disease were randomly assigned to the following three treatment groups for 8 weeks: simvastatin 5 mg/day (n = 10); losartan 50 mg/day (n = 9); or control (usual treatment; n = 8). Blood samples were collected before and after treatment. Results: Clinical characteristics and baseline cytokine levels were comparable among the three groups. Serum levels of M-CSF were significantly decreased only in the simvastatin group (from 403 ± 71 to 303 ± 116 pg/mL; p = 0.009). Plasma levels of TGF-β were significantly increased only in the losartan group (from 5.01 ± 1.13 to 7.50 ± 3.83 ng/mL; p = 0.021). Simvastatin decreased serum M-CSF levels independently of changes in total cholesterol or low-density lipoprotein-cholesterol. Conclusions: The results of this study indicate that simvastatin decreases serum levels of M-CSF while losartan increases plasma levels of TGF-β, suggesting that the two drugs may have different antiatherosclerotic properties.
AB - Background and objective: Use of HMG-CoA reductase inhibitors (statins) and angiotensin II type 1 (AT1) receptor antagonists reduces the incidence of cardiovascular events. The cytokines macrophage colony-stimulating factor (M-CSF) and transforming growth factor (TGF)-β may exert proatherogenic and antiatherogenic effects, respectively. In this study, we examined whether treatment with a statin or an AT1 receptor antagonist alters M-CSF and TGF-β levels in patients with coronary artery disease. Methods: Twenty-seven consecutive patients with coronary artery disease were randomly assigned to the following three treatment groups for 8 weeks: simvastatin 5 mg/day (n = 10); losartan 50 mg/day (n = 9); or control (usual treatment; n = 8). Blood samples were collected before and after treatment. Results: Clinical characteristics and baseline cytokine levels were comparable among the three groups. Serum levels of M-CSF were significantly decreased only in the simvastatin group (from 403 ± 71 to 303 ± 116 pg/mL; p = 0.009). Plasma levels of TGF-β were significantly increased only in the losartan group (from 5.01 ± 1.13 to 7.50 ± 3.83 ng/mL; p = 0.021). Simvastatin decreased serum M-CSF levels independently of changes in total cholesterol or low-density lipoprotein-cholesterol. Conclusions: The results of this study indicate that simvastatin decreases serum levels of M-CSF while losartan increases plasma levels of TGF-β, suggesting that the two drugs may have different antiatherosclerotic properties.
UR - http://www.scopus.com/inward/record.url?scp=33745494141&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745494141&partnerID=8YFLogxK
U2 - 10.2165/00129784-200606030-00004
DO - 10.2165/00129784-200606030-00004
M3 - Article
C2 - 16780390
AN - SCOPUS:33745494141
SN - 1175-3277
VL - 6
SP - 169
EP - 175
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 3
ER -